Kyverna Therapeutics
Kyverna Therapeutics is pioneering a new class of therapies and cures for serious autoimmune diseases.
About Kyverna Therapeutics
KYVERNA is pioneering a new class of treatments and potential cures for serious autoimmune diseases. The company's therapeutic platform combines advanced T-cell engineering and synthetic biology technologies to suppress and eliminate the autoreactive immune cells at the root cause of inflammatory diseases.
Company Facts
- Headquarters
- Berkeley
- Operating Status
- active
- Company Type
- for_profit
- IPO Status
- public
- Employees
- c_00101_00250
- Funding Stage
- ipo
- Total Funding
- $295,000,000
- Last Funding Type
- post_ipo_equity
- Last Funding Date
- 2025-12-17
- Website
- kyvernatx.com
Industries & Categories
Biotechnology, Life Science, Therapeutics
Social Links
Canonical: https://fsome.com/organization/kyverna-therapeutics-3756 · For the full interactive profile (funding rounds, investors, team, portfolio, charts), please enable JavaScript.